LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Longeveron statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Longeveron | Industry median |
|---|---|---|
| Market Cap | $44.32M | $166.30M |
| Enterprise Value | $34.24M | $88.19M |
| PS Ratio | 37.33 | 3.65 |
| PB Ratio | 4.26 | 2.03 |
| P/TBV Ratio | 5.40 | 2.29 |
Enterprise value
| Measure | Longeveron | Industry median |
|---|---|---|
| EV / Sales | 28.84 | 2.51 |
Income (trailing twelve months)
| Measure | Longeveron | Industry median |
|---|---|---|
| Revenue | $1.19M | $58.34M |
| Gross Profit | $828.00K | $105.94M |
| Operating Income | -$23.66M | -$21.40M |
| Net Income | -$23.47M | -$22.46M |
| EBITDA | -$22.86M | -$16.91M |
| EPS (Diluted) | -$0.77 | -$0.83 |
Margins
| Measure | Longeveron | Industry median |
|---|---|---|
| Gross Margin | 69.8% | 52.9% |
| Operating Margin | -1992.8% | -44.0% |
| Profit Margin | -1977.6% | -40.2% |
| EBITDA Margin | -1925.4% | -30.2% |
| FCF Margin | -1729.9% | -9.27% |
Returns
| Measure | Longeveron | Industry median |
|---|---|---|
| Return on Equity (ROE) | -203.6% | -53.2% |
| Return on Assets (ROA) | -145.6% | -40.9% |
| Return on Invested Capital (ROIC) | -1412.0% | -32.4% |
| Return on Capital Employed (ROCE) | -211.6% | -38.1% |
Growth
| Measure | Longeveron | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -42.7% | 5.96% |
| Revenue Growth (3Y CAGR) | -0.63% | 2.25% |
| Revenue Growth (5Y CAGR) | -26.6% | 6.48% |
Balance sheet
| Measure | Longeveron | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $10.08M | $61.43M |
| Net Cash (Debt) | $10.08M | $15.35M |
| Net Cash Per Share | $0.32 | $0.66 |
| Equity (Book Value) | $10.40M | $49.09M |
| Book Value Per Share | $0.33 | $1.37 |
| Tangible Book Value | $8.20M | $23.52M |
| Working Capital | $7.02M | $76.81M |
Financial position
| Measure | Longeveron | Industry median |
|---|---|---|
| Current Ratio | 2.63 | 3.34 |
| Quick Ratio | 2.35 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Longeveron | Industry median |
|---|---|---|
| Operating Cash Flow | -$20.37M | -$12.35M |
| Capital Expenditures | -$160.00K | -$1.08M |
| Free Cash Flow | -$20.53M | -$20.22M |
| FCF Per Share | -$0.64 | -$0.42 |
Efficiency
| Measure | Longeveron | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.39 |
| Revenue Per Employee | $32.08K | $404.87K |
| Profits Per Employee | -$634.43K | -$703.34K |
| Employee Count | 37 | 74 |
Dividends and yields
| Measure | Longeveron | Industry median |
|---|---|---|
| Earnings Yield | -53.0% | -23.3% |
| FCF Yield | -46.3% | -8.72% |
Shares
| Measure | Longeveron | Industry median |
|---|---|---|
| Shares Outstanding | 31,882,000 | 58,127,000 |
| Shares Change (YoY) | 49.6% | 10.9% |
| Float | 14,873,700 | 49,136,700 |
| Shares Held by Insiders | 53.3% | 11.6% |
Taxes
| Measure | Longeveron | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Longeveron | Industry median |
|---|---|---|
| Altman Z-Score | -12.13 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Longeveron's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.